TORONTO, April 4 /CNW/ - Amorfix Life Sciences Ltd. reported today that it has obtained the exclusive worldwide rights to additional novel targets on Superoxide Dismutase-1 (SOD1), which is a protein known to misfold and aggregate in the neurological disease Amyotrophic Lateral Sclerosis (ALS). These new SOD1 targets broaden Amorfix’s intellectual property estate on SOD1 and enhance its existing diagnostic and therapeutic strategies for the treatment of ALS. The company also obtained an option to acquire the intellectual property and know how surrounding the licensed technology.
